ClinicalTrials.gg
RecruitingNCT07670923Updated Nov 6, 2026

Comparison of Hemodynamics and Respiratory Function Between Ciprofol and Propofol in Elderly Patients Undergoing Non-intubated General Anesthesia

A Phase 4 interventional study of Propofol Injection and Ciprofol Injection in Comparison of Hemodynamics and Respiratory Function Between Ciprofol and Propofol in Elderly Patients Undergoing Non-intubated General Anesthesia, sponsored by General Hospital of Ningxia Medical University. Recruiting at 1 site in China. Open to participants aged 65 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by General Hospital of Ningxia Medical University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 6, 2026Eligibility revisedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
65 Years to 80 Years
Sex
All
01

Study summary

At the initiation of induction for non-intubated general anesthesia, ciprofol or propofol will be administered intravenously at a rate of 10 mL/min. The Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scale will be used to evaluate sedation depth. This study aims to assess the effects of ciprofol and propofol on hemodynamics and respiratory function in elderly patients undergoing non-intubated general anesthesia.

Read the detailed description

Inclusion Criteria (1)Elderly patients scheduled to undergo gastrointestinal endoscopy; (2)Aged 65-80 years; (3)American Society of Anesthesiologists (ASA) status of Ⅰ-Ⅲ; Exclusion Criteria

  1. Declined to participate in the study;
  2. Had known allergies or contraindications to benzodiazepines, ciprofol, propofol, or related compounds;
  3. Had a history of alcohol abuse or dependence on sedative-hypnotics drugs;
  4. Severe cardiovascular diseases, including uncontrolled hypertension(SBP ≥160 mmHg or DBP ≥100 mmHg despite medical treatment) or hypotension (SBP ≤90 mmHg or DBP ≤60 mmHg), resting bradycardia (heart rate \< 45 bpm), severe arrhythmia, heart failure, Adams-Stokes syndrome, unstable angina, myocardial infarction within the past 6 months, third-degree atrioventricular block, and QT interval ≥ 450 ms;
  5. Severe respiratory diseases, including respiratory insufficiency and chronic obstructive pulmonary disease(COPD), bronchospasm requiring treatment within the previous 3 months, acute respiratory infection accompanied by fever, wheezing, pulmonary rales or cough within the past week, predicted difficult airway(Mallampati grade Ⅳ), and baseline hypoxemia (SpO₂ \< 90%);
  6. Liver, kidney, blood system, nervous system, metabolic system or mental diseases with significant clinical significance;
  7. Severe gastrointestinal diseases such as gastric retention and persistent gastrointestinal bleeding;
  8. Demonstrated uncooperative behavior or impaired communication ability. Randomization and Group Allocation A total of 108 eligible elderly patients undergoing elective non-intubated general anesthesia at the Cardiovascular and Cerebrovascular Disease Hospital, General Hospital of Ningxia Medical University will be recruited. A computer-generated random number sequence will allocate subjects at a 1:1 ratio into the ciprofol group (Group C) and the propofol group (Group P).

Baseline Demographic Data Gender, age, height, weight, BMI, ASA classification, smoking history, alcohol consumption, underlying diseases, Modified Mallampati score, thyromental distance, snoring history, etc.

Outcome Measures

  1. Primary Outcome Measures Hemodynamic parameters:systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), heart rate (HR), cardiac output (CO), stroke volume (SV), and systemic vascular resistance (SVR) were recorded at the following time points: baseline before drug administration (T0), immediately after loss of consciousness (T1), at endoscope insertion (T2), and 1 min (T3), 2 min (T4), 3 min (T5), 4 min (T6), and 5 min (T7) after loss of consciousness.
  2. Incidence of respiratory-related adverse events: A respiratory-related adverse event was defined as the occurrence of any of the following events during sedation and anesthesia:

(1)Altered ventilation: respiratory rate (RR)\<8 bpm, or PETCO₂ decreased by more than 50% from baseline and lasting>30 s; (2)Apnea: cessation of thoracic movement during the procedure, or abruptly flattened PETCO₂ waveform lasting>15 s; (3)Hypoxemia: SpO₂\<93% lasting>15 s; (4)Severe hypoxemia: SpO₂ ≤ 85%. Anesthetic Protocol All patients maintained an 8-hour fast and a 4-hour liquid restriction preoperatively, with no preoperative medications administered. Standardized bowel preparation was completed within 24 hours.

After entering the room, the patients were placed in the left lateral position, received oxygen via nasal cannula at 6 L/min, and an upper extremity venous access was established. The non-invasive continuous arterial pressure and cardiac output monitoring system (Model:NICAP-T20A,Hunan Manite Medical Equipment Co., Ltd.) was used for continuous hemodynamic monitoring. A standard NIBP cuff was placed on the left upper arm for regular calibration. An ear clip sensor was attached to the right ear (the long handle end was placed inside the ear cavity close to the ear hole, and the curved end closely fitted the back of the ear), and a toe clip sensor was fixed at the root of the second or third toe of the right foot for continuous measurement. The system was manually calibrated every 1 min using brachial arterial blood pressure as the reference standard. The NICAP system continuously monitored hemodynamic parameters including systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), heart rate (HR), stroke volume (SV), cardiac output (CO), and systemic vascular resistance (SVR).Ventilation was monitored using a sidestream capnography (Model:KMI605C,Kingst). A pulse oximetry probe was connected, and a transnasal carbon dioxide sampling catheter was placed at the nasal vestibule to continuously sample exhaled gas. Respiratory rate (RR), pulse oxygen saturation (SpO₂), end-tidal carbon dioxide (PETCO₂) were recorded continuously.

Midazolam(Jiangsu Nhwa Pharmaceutical Co., Ltd.) 0.01 mg/kg was injected intravenously first. After the patient's circulation and respiration stabilized, the measured values were recorded as baseline data(T0). Ciprofol(Haisco Pharmaceutical Group Co., Ltd.) or propofol(Xi'an Libang Pharmaceutical Co., Ltd. ) was then infused intravenously at a rate of 10 mL/min. The modified observer's assessment of alertness/sedation (MOAA/S) scale was used to assess sedation depth every 5 seconds. Loss of consciousness was defined as MOAA/S score ≤ 1, at which drug administration was stopped, and the total induction dose of ciprofol or propofol was recorded. SBP, DBP, MAP, HR, SV,CO,SV and SVR were recorded at time points: before drug administration(T0), immediately after loss of consciousness(T1), immediately at endoscope insertion(T2), 1 min(T3), 2 min(T4), 3 min(T5), 4 min(T6) and 5 min(T7) after loss of consciousness. The incidence of respiratory-related adverse event was documented simultaneously. During anesthesia, anesthesiologists administered additional boluses of one-third of the initial induction dose of ciprofol or propofol according to the patient's responses such as eye opening, verbal response and body movement, with an interval of at least 1 min between injections.

During anesthesia, hypotension (SBP \< 90 mmHg, or MAP decreased by more than 20% from baseline and lasting >2 min) was treated with intravenous ephedrine 6 mg. Bradycardia (HR \< 45 bpm lasting >30 s) was managed with intravenous atropine 0.5 mg. In the event of altered ventilation (RR\< 8 bpm or PETCO₂ decreased by more than 50% from baseline and lasting > 30 s), apnea (cessation of thoracic movement or abruptly flattened PETCO₂ waveform lasting>15 s), hypoxemia (SpO₂ \< 93% lasting > 15 s), or severe hypoxemia ( SpO₂ ≤ 85%) . Anesthesiologists performed jaw thrust, increased oxygen flow, or provided mask-assisted ventilation; tracheal intubation was performed if necessary.

02

Conditions studied

  • Comparison of Hemodynamics and Respiratory Function Between Ciprofol and Propofol in Elderly Patients Undergoing Non-intubated General Anesthesia

Keywords

  • Ciprofol
  • Propofol
  • Aged
  • Non-intubated general anesthesia
  • Hemodynamics
  • Respiratory function
03

In context

Lead sponsor

General Hospital of Ningxia Medical University is the lead sponsor of 111 studies on the registry; 44 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 6, 2026. See what changed

Ages eligible
65 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria

  1. Elderly patients scheduled to undergo gastrointestinal endoscopy;
  2. Aged 65-80 years;
  3. (ASA) status of Ⅰ-Ⅲ; Exclusion Criteria

(1)Declined to participate in the study; (2)Had known allergies or to benzodiazepines, ciprofol, propofol, or related compounds; (3)Had a history of alcohol abuse or dependence on sedative-hypnotics drugs; (4)Severe cardiovascular diseases, including uncontrolled hypertension(SBP ≥160 mmHg or DBP ≥100 mmHg despite medical treatment) or hypotension (SBP ≤90 mmHg or DBP ≤60 mmHg), resting bradycardia (heart rate \< 45 bpm), severe arrhythmia, heart failure, Adams-Stokes syndrome, unstable angina, myocardial infarction within the past 6 months, third-degree atrioventricular block, and ≥ 450 ms; (5)Severe respiratory diseases, including respiratory insufficiency and (COPD), bronchospasm requiring treatment within the previous 3 months, acute respiratory infection accompanied by fever, wheezing, pulmonary rales or cough within the past week, predicted difficult airway(Mallampati grade Ⅳ), and baseline hypoxemia (SpO₂ \< 90%); (6)Liver, kidney, blood system, nervous system, metabolic system or mental diseases with significant clinical significance; (7)Severe gastrointestinal diseases such as gastric retention and persistent gastrointestinal bleeding; (8)Demonstrated uncooperative behavior or impaired communication ability.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    Ciprofol treatment group

    This group plans to enroll a total of 54 elderly patients aged 65-80 who will undergo brief procedures without intubation, using spontaneous respiration under general anesthesia. The intravenous infusion of cyclopropane hydrochloride injection will be administered at a constant rate of 10 ml/min. The administration will cease when the MOAA/S score is ≤1. Throughout the procedure, hemodynamic parameters (HR, SBP, DBP, MAP, CO, SV,SVR) will be monitored within the first 5 minutes after induction. The incidence of respiratory-related adverse event was documented simultaneously. The safety of the medication will be evaluated in comparison with the control group

    Drug: Ciprofol Injection

  • Active comparator
    Propofol Control group

    This study aims to enroll 54 elderly patients aged 65-80 with short procedures and no need for intubation, who will receive propofol intravenously at a constant rate of 10 ml/min until their MOAA/S score drops to ≤1 point. Throughout the procedure, hemodynamic parameters (HR, SBP, DBP, MAP, CO, SV,SVR) will be monitored within the first 5 minutes after induction. The incidence of respiratory-related adverse event was documented simultaneously. This will allow for a parallel comparison of the two medications' effects on the circulatory and respiratory systems of elderly patients with the propofol control group.

    Drug: Propofol Injection

Interventions

  • DrugPropofolStudies of PropofolPropofol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravenous administration, injection rate of 10 ml/min, continuous and uniform infusion until the patient's MOAA/S sedation score is ≤1 point. This is used for the induction of general anesthesia in short-duration medical procedures for elderly individuals aged 65-80 without intubation and with spontaneous respiration

  • DrugCiprofolStudies of CiprofolCiprofol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravenous administration, injection rate of 10 ml/min, continuous and uniform infusion until the patient's MOAA/S sedation score is ≤1 point. This is used for the induction of general anesthesia in short-duration medical procedures for elderly individuals aged 65-80 without intubation and with spontaneous respiration

06

What researchers measure

Primary outcomes

  1. Comparison of hemodynamic and respiratory function changes within 5 minutes of anesthesia induction

    The primary objective of this study was to evaluate the degree of circulatory and respiratory suppression induced by two types of anesthesia drugs in elderly patients. Continuous, non-invasive monitoring was conducted on the baseline conditions before administration for patients aged 65 to 80 undergoing short procedures without intubation and with spontaneous respiration under general anesthesia. Additionally, measurements were taken at 1 minute, 2 minutes, 3 minutes, 4 minutes, and 5 minutes after induction to assess circulatory and respiratory functions. Statistical analysis was performed to compare the changes in Heart rate, systolic blood pressure, diastolic blood pressure, mean arterial pressure, cardiac output , stroke volume, systemic vascular resistance , peripheral oxygen saturation within the 5-minute induction period and incidence of respiratory-related adverse events.

    Time frame: 5 minutes after induction of anesthesia

Secondary outcomes

  1. Other adverse events:

    Other adverse events: injection pain, cough, hypotension (SBP\<90 mmHg, or MAP decreased by more than 20% from baseline and lasting \>2 min), bradycardia (HR \< 45 bpm lasting \>30 s).

    Time frame: during anesthesia

07

Study locations

1 of 1 sites recruiting
  • Cardiovascular and Cerebrovascular Disease Hospital, General Hospital of Ningxia Medical University
    Yinchuan, Ningxia 750000, China
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Feb 2027, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2026
First posted
Jun 26, 2026
StartActual
Jul 1, 2026
Primary completionEst.
Feb 1, 2027
CompletionEst.
Apr 1, 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
Criteria largely rewritten (14 changes)
What changed in the criteria
  • AddedInclusion Criteria
  • AddedElderly patients scheduled to undergo gastrointestinal endoscopy;
  • AddedAged 65-80 years;
  • EditedAmerican Society of Anesthesiologists (ASA) physical status class Iof Ⅰ-IIIⅢ; Exclusion Criteria
  • Added(1)Declined to participate in the study; (2)Had known allergies or contraindications to benzodiazepines, ciprofol, propofol, or related compounds; (3)Had a history of alcohol abuse or dependence on sedative-hypnotics drugs; (4)Severe cardiovascular diseases, including uncontrolled hypertension(SBP ≥160 mmHg or DBP ≥100 mmHg despite medical treatment) or hypotension (SBP ≤90 mmHg or DBP ≤60 mmHg), resting bradycardia (heart rate < 45 bpm), severe arrhythmia, heart failure, Adams-Stokes syndrome, unstable angina, myocardial infarction within the past 6 months, third-degree atrioventricular block, and QT interval ≥ 450 ms; (5)Severe respiratory diseases, including respiratory insufficiency and chronic obstructive pulmonary disease(COPD), bronchospasm requiring treatment within the previous 3 months, acute respiratory infection accompanied by fever, wheezing, pulmonary rales or cough within the past week, predicted difficult airway(Mallampati grade Ⅳ), and baseline hypoxemia (SpO₂ < 90%); (6)Liver, kidney, blood system, nervous system, metabolic system or mental diseases with significant clinical significance; (7)Severe gastrointestinal diseases such as gastric retention and persistent gastrointestinal bleeding; (8)Demonstrated uncooperative behavior or impaired communication ability.
Inclusion criteria
  • RemovedPatients scheduled for elective non-intubated general anesthesia
  • RemovedAge ranging from 65 to 80 years old
  • RemovedWritten informed consent signed by the patient or legal guardian
Exclusion criteria
  • RemovedConfirmed allergy to propofol, ciprofol or their excipients
  • RemovedSevere cardiovascular diseases (uncontrolled hypertension, heart failure, severe arrhythmia, etc.)
  • RemovedSevere respiratory diseases (chronic obstructive pulmonary disease, obstructive sleep apnea syndrome, etc.)
  • RemovedSevere hepatic or renal insufficiency
  • RemovedLong-term regular use of sedatives or opioids
  • RemovedBaseline bradycardia (HR < 50 beats/min) or hypoxemia (SpO₂ < 90%)
Nov 6, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionComparison of hemodynamic and respiratory function changes within 5 minutes of anesthesia induction: how it is measured was reworded
Nov 6, 2026
Secondary outcomes
1 added, 2 removed
What changed in the outcomes
  • AddedOther adverse events:Time frame: during anesthesia
  • RemovedBrain electrical activity sedation depth (BIS)Time frame: 5 minutes after induction of anesthesia
  • Removedincidence of induction period circulatory/respiratory adverse eventsTime frame: 5 minutes after induction of anesthesia
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Eligibility Criteria largely rewritten (14 changes)
    What changed in the criteria
    • AddedInclusion Criteria
    • AddedElderly patients scheduled to undergo gastrointestinal endoscopy;
    • AddedAged 65-80 years;
    • EditedAmerican Society of Anesthesiologists (ASA) physical status class Iof Ⅰ-IIIⅢ; Exclusion Criteria
    • Added(1)Declined to participate in the study; (2)Had known allergies or contraindications to benzodiazepines, ciprofol, propofol, or related compounds; (3)Had a history of alcohol abuse or dependence on sedative-hypnotics drugs; (4)Severe cardiovascular diseases, including uncontrolled hypertension(SBP ≥160 mmHg or DBP ≥100 mmHg despite medical treatment) or hypotension (SBP ≤90 mmHg or DBP ≤60 mmHg), resting bradycardia (heart rate < 45 bpm), severe arrhythmia, heart failure, Adams-Stokes syndrome, unstable angina, myocardial infarction within the past 6 months, third-degree atrioventricular block, and QT interval ≥ 450 ms; (5)Severe respiratory diseases, including respiratory insufficiency and chronic obstructive pulmonary disease(COPD), bronchospasm requiring treatment within the previous 3 months, acute respiratory infection accompanied by fever, wheezing, pulmonary rales or cough within the past week, predicted difficult airway(Mallampati grade Ⅳ), and baseline hypoxemia (SpO₂ < 90%); (6)Liver, kidney, blood system, nervous system, metabolic system or mental diseases with significant clinical significance; (7)Severe gastrointestinal diseases such as gastric retention and persistent gastrointestinal bleeding; (8)Demonstrated uncooperative behavior or impaired communication ability.
    Inclusion criteria
    • RemovedPatients scheduled for elective non-intubated general anesthesia
    • RemovedAge ranging from 65 to 80 years old
    • RemovedWritten informed consent signed by the patient or legal guardian
    Exclusion criteria
    • RemovedConfirmed allergy to propofol, ciprofol or their excipients
    • RemovedSevere cardiovascular diseases (uncontrolled hypertension, heart failure, severe arrhythmia, etc.)
    • RemovedSevere respiratory diseases (chronic obstructive pulmonary disease, obstructive sleep apnea syndrome, etc.)
    • RemovedSevere hepatic or renal insufficiency
    • RemovedLong-term regular use of sedatives or opioids
    • RemovedBaseline bradycardia (HR < 50 beats/min) or hypoxemia (SpO₂ < 90%)
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionComparison of hemodynamic and respiratory function changes within 5 minutes of anesthesia induction: how it is measured was reworded
    Secondary outcomes 1 added, 2 removed
    What changed in the outcomes
    • AddedOther adverse events:Time frame: during anesthesia
    • RemovedBrain electrical activity sedation depth (BIS)Time frame: 5 minutes after induction of anesthesia
    • Removedincidence of induction period circulatory/respiratory adverse eventsTime frame: 5 minutes after induction of anesthesia
    + 2 other changes: description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07670923
Responsible party
Sponsor
First posted
Jun 26, 2026
Start date
Jul 1, 2026
Primary completion
Feb 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Hanxiang Ma Ma, master
Contact
mahanxiang@hotmail.com
13519591508
LI Mo Mo, Bachelor
Contact
ml185030153@163.com
17752025907

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ciprofol

Start the discussion